Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
Executive Summary
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
You may also be interested in...
With Innovative Purdue Deal, Infinity Finds Shelter From The Storm
In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.
Discovery Finalizing Surfaxin “Complete Response,” Eyes 2008 Approval
Firm plans response to May 1 “approvable” letter that addresses biological activity test criteria, lipid-related impurities.
Ipsen Acquisition Trifecta Raises North American Stakes
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.